Jazz Pharmaceuticals officer proposes $1.38M sale

The notice also lists three earlier sales of 6,000 shares each, dated July 1, August 3 and September 1, 2026.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc officer Bruce C. Cozadd reported a proposed sale of 6,000 common shares, with an aggregate market value of $1,381,980 and an approximate sale date of October 1, 2026. Merrill Lynch is identified as the broker and NASDAQ as the exchange. The notice lists 64,914,577 common shares outstanding and stock-option entries for 4,393 shares dated March 1, 2018, and 1,607 shares dated March 5, 2025.

Key Figures

Proposed common shares: 6,000 shares Aggregate market value: $1,381,980 Common shares outstanding: 64,914,577 shares +5 more

8 metrics

Proposed common shares 6,000 shares Proposed sale

Aggregate market value $1,381,980 Proposed sale

Common shares outstanding 64,914,577 shares As listed in the securities information

Shares with stock-option entry 4,393 shares Entry dated March 1, 2018

Shares with stock-option entry 1,607 shares Entry dated March 5, 2025

Gross proceeds $1,442,820 6,000 shares sold July 1, 2026

Gross proceeds $1,517,880 6,000 shares sold August 3, 2026

Gross proceeds $1,500,780 6,000 shares sold September 1, 2026

Key Terms

Rule 144, Stock Option

2 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option financial

"Stock Option | Jazz Pharmaceuticals PLC"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JAZZ shares did Bruce Cozadd propose to sell?

Bruce C. Cozadd reported a proposed sale of 6,000 common shares, with an aggregate market value of $1,381,980. The notice gives an approximate sale date of October 1, 2026, and identifies Merrill Lynch as the broker.

What proceeds were reported for Bruce Cozadd's recent JAZZ share sales?

The notice lists gross proceeds of $1,442,820 for 6,000 shares sold July 1, 2026; $1,517,880 for 6,000 shares sold August 3, 2026; and $1,500,780 for 6,000 shares sold September 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:32 PM Accepted by SEC EDGAR 10/01/2026 - 04:32 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001193210
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jazz Pharmaceuticals Plc
SEC File Number	001-33500
Address of Issuer	5th Floor Waterloo Exchange Waterloo Road Dublin IRELAND D04 E5W7
Phone	353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	Bruce C Cozadd
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3075A Hansen Way 1st Floor Palo Alto CA 94304	6000	1381980	64914577	10/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2018	Stock Option	Jazz Pharmaceuticals PLC			4393	03/01/2018	Cash
Common	03/05/2025	Stock Option	Jazz Pharmaceuticals PLC			1607	03/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bruce Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin L2 D04-E5W7	Common	09/01/2026	6000	1500780
Bruce Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin L2 D04-E5W7	Common	08/03/2026	6000	1517880
Bruce Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin L2 D04-E5W7	Common	07/01/2026	6000	1442820

144: Remarks and Signature

Remarks
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Bruce C Cozadd
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)